CytoDyn
CytoDyn Appoints Robert E. Hoffman Chief Executive Officer
CytoDyn announced a leadership change on October 19, 2026. CytoDyn appointed Robert E. Hoffman, who joined as its CFO in May 2025, as CEO, succeeding Dr. Jacob Lalezari, with a focus on clinical execution and financial discipline.
What changed
Robert E. Hoffman was named Chief Executive Officer. Dr. Jacob Lalezari, CEO since November 2023, will remain with the company as Head of Research and Translational Sciences, focusing on new leronlimab opportunities in solid-tumor oncology.
- Leader: Robert E. Hoffman
- Role: Chief Executive Officer
- Effective: October 20, 2026
- Announcement date: October 19, 2026
Leadership background
Hoffman joined CytoDyn as Chief Financial Officer on May 15, 2025, and will continue as the company’s principal accounting officer. His prior roles include President, CEO, interim Chief Financial Officer, and Chairperson of the board at Kintara Therapeutics, and Chief Financial Officer positions at Heron Therapeutics, Innovus Pharmaceuticals, and AnaptysBio. He started at Arena Pharmaceuticals, rising to Senior Vice President, Finance and Chief Financial Officer, and currently serves on the boards of TuHURA Biosciences and Fibrobiologics.
The mandate
CytoDyn said Hoffman cited clinical execution, financial discipline, and positioning the company for its next stage of growth as priorities. Lalezari framed 2027 as a year of clinical results, regulatory progress, and renewed partnering opportunities.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: CytoDyn leadership announcement.
Related Reports
Onward Energy Appoints Patrick Welch Chief Executive Officer
Onward Energy announced the appointment of Patrick Welch, its CFO since 2023 and Interim President and CEO, as Chief Executive Officer, effective October 27, 2026.
Tully Luxury Travel Names Steven Salm Chief Executive Officer
Tully Luxury Travel named Steven Salm CEO, succeeding founder Mary Jean Tully, who stepped down after nearly four decades and stays on as Brand Ambassador; Salm will lead day-to-day operations and growth.
Harper Names Lelah Manz Chief Executive Officer
Harper appointed former Akamai executive Lelah Manz as CEO, succeeding co-founder Stephen Goldberg.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free